NCT06478264

A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma: a Single-arm, Multicenter, Phase II Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Zhangzhou Municipal Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of adebrelimab combined with chemoradiotherapy in the treatment of esophageal small cell carcinoma

Conditions

• Esophageal Small Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Etoposide	100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles
DRUG	Cisplatin	25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles
DRUG	Carboplatin	Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;
DRUG	Adebrelimab	1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.
RADIATION	radiotherapy	Stage I-IVa , prescription dose: PTV 50Gy/25f. Stage IVb ,prescribed dose: PTV 30Gy/10f.

Timeline

• Start date: 2024-07-13
• Primary completion: 2026-07-13
• Completion: 2027-07-13
• First posted: 2024-06-27
• Last updated: 2024-06-27